



WEDNESDAY, 10th APRIL 2019 COMMENCING 10:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

Enclosure

1. **Welcome and introduction**

2. **Apologies**

3. **Declarations of interest**

4. **Minutes of previous meeting**

1/AWMSG/0419

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Limited Submission (PAS)**

Blinatumomab (Blincyto[®]) as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation

2/AWMSG/0419
Appendices

6. **Appraisal 2: Limited Submission (PAS)**

Mepolizumab (Nucala[®]) as add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older

3/AWMSG/0419
Appendices

The meeting will now open to the public for the committee decisions

7. **Chairman's report (verbal update)**

Date of next meeting – Wednesday, 15th May 2019 in Cardiff